Finally, while adenoviral peptide delivery may not be a practical therapeutic modality, our findings suggest that interventions using or mimicking the FAK-derived peptide may translate to in vivo models and increase tumor-free survival by mitigating pressure-stimulated tumor adhesion. The gene discussed is PTK2; the disease is neoplasm.